The ADRA2C gene encodes the alpha-2C adrenergic receptor (α2C-AR), a G protein-coupled receptor that mediates sympathetic tone inhibition. The α2C subtype is widely expressed in the central nervous system and peripheral tissues, playing crucial roles in regulating norepinephrine signaling, autonomic function, and stress responses. The receptor is unique among α2-AR subtypes for its distinctive subcellular distribution and functional properties.
| ADRA2C Gene |
|---|
| Gene Symbol | ADRA2C |
| Full Name | Adrenoceptor Alpha 2C |
| Chromosomal Location | 4p16.3 |
| NCBI Gene ID | [152](https://www.ncbi.nlm.nih.gov/gene/152) |
| Ensembl ID | ENSG00000141449 |
| UniProt ID | [P21917](https://www.uniprot.org/uniprot/P21917) |
| Protein Size | 462 amino acids |
¶ Transmembrane Domain Architecture
ADRA2C encodes a 462-amino acid GPCR with canonical seven transmembrane domain structure:
- 7 TM Helices (TM1-TM7): Canonical GPCR structure forming the ligand-binding pocket
- Disulfide Bond: Conserved cysteine in extracellular loop 2 that stabilizes receptor structure
- N-linked Glycosylation Sites: N-terminal extracellular domain for proper folding and trafficking
- Conserved Motifs: DRY motif in TM3 for G protein coupling, NPxxY in TM7 for activation
¶ Functional Domains
| Domain |
Location |
Function |
| N-terminus |
Extracellular |
Glycosylation, ligand access |
| Extracellular loops |
ECL1-3 |
Minor ligand binding contribution |
| Transmembrane core |
TM1-7 |
Major ligand binding site |
| Cytoplasmic loops |
ICL1-3 |
G protein coupling interface |
| C-terminal tail |
Cytoplasmic |
G protein coupling, phosphorylation sites, arrestin binding |
Alpha-2C adrenergic receptor signals primarily through Gi/o protein pathways:
- Adenylate Cyclase Inhibition: Gi/o coupling reduces cAMP production via inhibition of adenylate cyclase
- GIRK Channel Activation: Activation leads to G protein beta-gamma subunit-mediated activation of GIRK channels, causing membrane hyperpolarization
- MAPK Pathways: Can activate alternative signaling cascades including ERK1/2 and p38 pathways
- PLC Inhibition: In some tissues, Gi/o signaling can inhibit phospholipase C activity
| Property |
Details |
| Agonists |
Norepinephrine, epinephrine, clonidine, dexmedetomidine, guanfacine |
| Antagonists |
Yohimbine, rauwolscine, idazoxan, atipamezole |
| Desensitization |
GRK-mediated phosphorylation, beta-arrestin recruitment |
| Internalization |
Arrestin-dependent and independent pathways |
| Inverse Agonists |
Several compounds that reduce constitutive activity |
flowchart TD
A["Norepinephrine<br/>Epinephrine"] --> B["α2C-AR"]
B --> C["Gi/o Protein"]
C --> D["Adenylate Cyclase"]
D --> E["cAMP Reduction"]
C --> F["GIRK Channels"]
F --> G["K+ Efflux<br/>Hyperpolarization"]
E --> H["Reduced PKA Activity"]
G --> I["Reduced Neuronal Firing"]
H --> J["Reduced neurotransmitter<br/>release"]
style I fill:#c8e6c9,stroke:#333
style J fill:#c8e6c9,stroke:#333
- Sympathetic Inhibition: Reduces sympathetic outflow by inhibiting norepinephrine release
- Neuronal Inhibition: Hyperpolarizes postsynaptic neurons through GIRK activation
- Presynaptic Autoreceptor: Regulates norepinephrine release from sympathetic nerve terminals
- Thermoregulation: Mediates cutaneous vasoconstriction in response to cold
- Analgesia: Spinal α2C-AR contributes to pain modulation
- Sedation: Central sedative effects of α2-AR agonists
- Cognitive Function: Modulates attention, memory, and executive function
α2C-AR exhibits distinct regional distribution:
- Cerebral Cortex: Layer-specific expression, particularly in prefrontal cortex
- Hippocampus: CA1-CA3 regions, dentate gyrus
- Basal Ganglia: Striatum (caudate and putamen), substantia nigra pars compacta
- Spinal Cord: Dorsal horn (pain transmission pathways)
- Locus Coeruleus: Noradrenergic cell bodies (presynaptic autoreceptors)
- Hypothalamus: Neuroendocrine regulation, particularly paraventricular nucleus
- Platelets: Regulates platelet aggregation
- Adipose Tissue: Modulates lipolysis and thermogenesis
- Vasculature: Controls vascular tone, especially in cutaneous circulation
- Pancreas: Modulates insulin secretion from beta cells
- Kidney: Influences renin secretion and renal function
In Alzheimer's disease:
- Altered α2C-AR expression in AD brain, with reduced cortical receptor density
- Contributes to noradrenergic dysfunction characteristic of AD
- Loss of cortical α2C-AR in early AD may serve as a biomarker
- Interaction with amyloid pathology through modulation of synaptic function
- Potential therapeutic target for cognitive enhancement
In Parkinson's disease:
- Dysregulated α2-AR signaling in PD patients
- Altered autonomic function contributes to non-motor symptoms
- May affect levodopa response and motor complications
- α2-AR antagonists may have potential in treating PD psychosis
- Blunted hypothermic response to α2-AR agonists observed
The noradrenergic system is implicated in depression[@michelm2014]:
- α2-AR antagonists (e.g., yohimbine) have antidepressant effects in some patients
- Dysregulated receptor function in major depressive disorder
- Supports the noradrenergic hypothesis of depression
- α2C-AR subtype may be particularly relevant to emotional processing
- Anxiety Disorders: α2C-AR role in fear and stress responses
- Pain: Spinal α2C-AR contributes to analgesic effects of α2-AR agonists
- ADHD: α2-AR agonists (guanfacine) used for attention enhancement
- Post-traumatic stress disorder: Altered adrenergic receptor function
| Drug |
Type |
Application |
| Clonidine |
Agonist |
Hypertension, ADHD, opioid withdrawal |
| Dexmedetomidine |
Agonist |
ICU sedation, perioperative analgesia |
| Guanfacine |
Agonist |
ADHD, hypertension |
| Yohimbine |
Antagonist |
Depression, orthostatic hypotension |
| Brimonidine |
Agonist |
Glaucoma, ocular hypertension |
- α2C-AR modulation for cognitive enhancement in AD/PD
- Selective antagonists for treatment-resistant depression
- Pain management strategies combining spinal and supraspinal mechanisms
- Combination with dopaminergic therapies in PD
Current research focuses on:
- Developing subtype-selective ligands with improved CNS penetration
- Understanding α2C-AR specific role in neurodegeneration
- Gene therapy approaches for direct receptor modulation
- Biomarker development using receptor imaging